4 secrets to being pitch perfect from a startup founder

Down pat

Whether you're pitching your startup in a competition or for capital, here are some expert tips. Getty Images

One of the things our team at EllieGrid is most famous for is pitching. We have pitched our smart pill box in over 20 business plan competitions, on television, radio, and to so many investors that I have lost count. I can't remember what our first pitch was like but I know it has certainly evolved overtime. You could even say that we A/B tested some of our methods.

When you first organize your thoughts, you want to consider the basics, so before I give my advice, consider these tried-and-true tips.

  • Get to the point — say what your company is in the first 10 seconds
  • Know your audience
  • Shorter usually means better
  • Keep numbers to a minimum
  • Have a clear ask

In order to save you a little time, here are some of the of the lessons I learned the hard way to help you perfect your pitch.

Don't pitch. Tell a story.
I am going to let you in on a little secret: most people don't want to hear your pitch, especially if yours is not the first they have heard that day. Put yourself in their shoes, do you really want to listen to someone ramble on about facts and figures? Chances are, no. Instead, tell a story. Use engaging voices and set the scene. Recall your creative writing classes from high school and how you should mention what it was like in terms of feel, smell, taste, etc. and don't use generic adjectives such as "too small" or "the old way was hard."

People remember how you made them feel
What is in it for your audience? Is it wealth, power, fame, praise or glory, and/or pleasure? It might sound obvious to make this point when pitching, but I suggest you write out your pitch and highlight exactly where you say what is in it for them, maybe even more than once. Making the audience feel like you are caring about their desires and engaging them in conversation will help you be more memorable.

Come full circle
My favorite technique in any pitch or speech is if the speaker can connect the closing back to something they said at the beginning of their pitch. I enjoy this because sometimes the speaker will leave a question unanswered and then reveal how their solution is the answer in a creative way. This keeps your listeners engaged and connects the pain to your solution. Watch a few TED talks and you will see what I mean.

Pitch to a kid
This is probably the best advice I can give because it is a surefire way to make sure your pitch makes sense to a wide range of listeners. This also forces you to leave out jargon and filler words that you think might make you sound fancy like "innovative" or "disruptive" but actually make you sound like everyone else.

------

Regina Vatterott is the COO and co-founder of Ellie Grid, a Houston-based company reinventing medical devices. Read more about Regina here.

Youngro Lee, co-founder and CEO of NextSeed, wants to create a connection between business and their communities. Courtesy of NextSeed

Houston startup founder plants the seeds for innovative capital raising

Growing investments

After eight years as a private equity lawyer, Youngro Lee quit his job to start NextSeed, a digital avenue for businesses to raise capital from the community they serve.

"One thing that I always realized in my professional career is that private equity is not the stock market," Lee says. "It's only open to wealthy, accredited individuals. I didn't like that. I thought it was in inefficient process. It's really hard for entrepreneurs to raise money if it's only open to this small group of people."

Since its founding in 2015, NextSeed has helped dozens of companies — like restaurant group, Peli Peli, and brewery, Buffalo Bayou Brewing Co. — raise money online from individual investors.

"Our mission is to connect businesses and individuals to their communities," Lee says. "That's why our businesses and the people we work with are largely focused on retail or consumer-facing businesses. No matter how our company evolves, we will stick to that as much as possible."

NextSeed is expected to grow and evolve its services in the near future.

InnovationMap: What changed so that NextSeed could exist?

Youngro Lee: When the Jobs Act happened in 2012, essentially a series of laws allowed for online fundraising for companies — including to non-accredited investors. That really caught my eye. I decided to leave my legal career to leverage this new law to start NextSeed, which is a platform for businesses to raise capital for from anybody.

IM: What were your first steps in starting NextSeed?

YL: It was really just understanding the changing law to really come to the conclusion that this could work — and then understanding the parameters that need to be put in place to make it happen. And then there's no easy way to do it, so I just quit my jobs and went for it.

IM: How did NextSeed get its initial funding?

YL: We found angel investors to get the company started. As we made some progress over time, we found some other investors along the way.

IM: How is NextSeed different from anything else out there?

YL: For businesses, it's a completely different way to raise capital. We find businesses legally compliant ways to raise money and put it online, and they get to engage with the community through their page.

IM: How is it different from crowdfunding sites?

YL: There are so many different types of crowdfunding platforms. What we're doing is investment or securities crowdfunding. Kickstarter, for instance, is asking for support or donations with a reward, but NextSeed is allowing for investing in financial securities that's being issued by the businesses. Even amongst the investment crowdfunding platforms, there's usually a focus on specific assets, like real estate, tech startups, or small businesses — that's what NextSeed focuses on, small businesses debt securities.

IM: How do you get new clients and relationships?

YL: A lot of it really is people to people. Investors telling people about it, and businesses telling other businesses about a new way to raise capital.

IM: What do you wish you'd known before you started NextSeed?

YL: Nothing ever goes to plan. I think especially for startups, there's a lot of accomplished companies out there, and a lot will try to give you advice or support. It's helpful, but the reality is that circumstances of a startup is so unique that you really have to be flexible to the feedback from the market when you're starting your business or launching your product.

IM: How does Houston's startup community compare to other major cities?

YL: I think it's changed dramatically. When I started in 2014, there was nothing like what there is now. There was nothing like Station Houston or Houston Exponential. In general, the Houston community has really embraced and has an interest in what a startup is and how it can make a good impact on the Houston economy.

IM: How has startup funding changed throughout your career?

YL: There's definitely more people interested in investing in startups, but a lot of misconceptions on both sides — companies and investors — on what a startup needs in terms of support. It is a lot better now than it was four years ago. I think the key for Houston to understand is Silicon Valley is Silicon Valley. New York is New York. Houston's innovation ecosystem is really different from other markets. I think Houston needs to find what works for Houston and not necessarily replicate what other markets seem to be doing.

IM: What's a mistake you've made in your career and what did you learn from it?

YL: There's so many. One I made, and I keep making, is as a startup founder you're so used to doing everything in a specific way. I've definitely held on to more responsibilities or decisions that I should have delegated and entrusting others to do them. As you get to different stages as a startup you have to grow the organization. What I've learned from not being able to give up control or be more flexible is that it doesn't work. It's a team effort, and you need every member of the team to feel empowered and part of the entire process.

IM: How has NextSeed's team grown over the past four years?

YL: NextSeed started with three co-founders and now we have around 18 people. We are definitely still in transition process from a mature startup to an innovative financial institution. We are officially becoming a broker-dealer to be able to service a larger base — financial side, business side, as well as our investors. The goal was for NextSeed to keep innovating and bring in new technologies and processes

IM: What's next for NextSeed?

YL: Over the next couple month we will be expanding our capabilities to work on larger projects and different types of investment opportunities.

IM: What keeps you up at night, as it pertains to your business?

YL: As a startup, "almost good" doesn't work. You have to get it right because competition and standards are so much higher for startups. So, especially given that we are focused on technology and finance, I want to make sure we set ourselves up for a high standards and meet expectations.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings